biotech

ElectroCore shares absolutely exploded on Friday after the company announced an update for its COVID-19 treatment.
Chris Lange
Becton, Dickinson is officially throwing its hat in the ring to fight COVID-19. Specifically, this firm is working on the front end by testing for the disease and antibodies that have been built up...
Chris Lange
InflaRx shares jumped early on Wednesday after the company announced that it has enrolled its first patient into a clinical trial for the treatment of severe COVID-19-induced pneumonia.
Chris Lange
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
Paul Ausick
Co-Diagnostics is on many shortlists of companies with partial medical solutions to slow the coronavirus outbreak. Investors have been on a roller-coaster ride. Is the stock ready to run?
Douglas A. McIntyre
Trinity Biotech released its fiscal fourth-quarter financial results on Tuesday morning, but that wasn’t what propelled the stock afterward.
Chris Lange
Bio-Path stock has taken a beating in the past five years. Investors obviously aren’t happy about this, and the way that management and the board of directors has handled it has been clumsy.
Chris Lange
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Chris Lange
U.S. consumer confidence continues to decline, but the slide has slowed. On Sunday, the FDA and the Department of Health and Human Services okayed two drugs for use in the fight against COVID-19.
Paul Ausick
Dynavax Technologies shares made a handy gain on Thursday after the company announced that it would be entering the coronavirus vaccine business. Is the market for these vaccines getting...
Chris Lange
The March 13 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Chris Lange
SunTrust Robinson Humphrey has issued a new Buy rating Compugen, and the firm's target price represents more than 100% in implied upside from the prior close.
Jon C. Ogg
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this coronavirus and here is where their stocks stand now.
Chris Lange
GenMark Diagnostics stock has really not made any of the zany exponential gains that have been seen in other coronavirus-related stocks.
Jon C. Ogg
Aytu BioScience was largely unknown until it announced that it had a test for COVID-19. Since then, it has seen a meteoric rise in its common stock price. Does the future look bright?
Chris Lange